**research proposal**(FIRST CALL: 1st juLY – 30th september, 2023)  
version: 20230628

|  |
| --- |
| ***Remove this box, it must not be included in the proposal***  ***General Instructions***   * *The proposal must be written in English* * *Calibri font 12 points. Text inside tables 9 points* * *Hyperlinks must be avoided as they will not be open by the evaluators.* * *Footnotes are to be used exclusively for literature references*, *font size 8. Footnotes text is included in the page limit.* * *Rename the file to: CIBER\_area\_SurnameName\_Proposal.pdf* * *The maximum length of the research proposal is 14 pages, ethical checklist and mobility track record are not included. Pages exceeding this length will not be taken into account.*   ***Language***   * *Figures/tables/charts/diagrams are allowed to illustrate the text appropriately.* * *Explain any abbreviations the first time used.* * *Use simple clear text, make sure that it ‘reads well’.* |

Contents

[Information 3](#_Toc138862048)

[Acronym and title of the proposal (max 100 characters) 3](#_Toc138862049)

[Summary (Max 200 words) 3](#_Toc138862050)

[Keywords 3](#_Toc138862051)

[I. EXCELLENCE 4](#_Toc138862052)

[I.1 Introduction: background and context 4](#_Toc138862053)

[I.2 Concept and objectives 4](#_Toc138862054)

[I.3 Research methodology including multidisciplinary approach 4](#_Toc138862055)

[I.4 Innovation and originality 4](#_Toc138862056)

[I.5 Suitability of the selected company 4](#_Toc138862057)

[I.6 Open Sciences practices 4](#_Toc138862058)

[II. IMPACT 5](#_Toc138862059)

[II.1 Identified CIBER hosting group and integration with the group 5](#_Toc138862060)

[II.2 Expected outcomes: impact of your research 5](#_Toc138862061)

[II.3 Measures for communication, exploitation and dissemination 5](#_Toc138862062)

[II.4 Potential industry/clinical collaborations 5](#_Toc138862063)

[III. IMPLEMENTATION 6](#_Toc138862064)

[III.1 Work Plan 6](#_Toc138862065)

[III.2 Match of the host group 7](#_Toc138862066)

[ETHICAL ISSUES 8](#_Toc138862067)

[APPENDIX 1: MOBILITY TRACK 10](#_Toc138862068)

[APPENDIX 2: KEYWORDS 10](#_Toc138862069)

# information

|  |  |
| --- | --- |
| **Personal Information** | |
| Name (middle name) \* |  |
| Surname 1 \* |  |
| Surname 2 |  |
| Passport number ID |  |

|  |  |
| --- | --- |
| **Other Information** | |
| Proposed Hosting Group: | *(example: CB/00/00/0000)* |
| Proposed Secondment Company |  |

# acronym and Title of the proposal (max 100 characters)

# SUMMARY (Max 200 words)

# KEYWORDS

*Select Type 1 and Type 2 from the Appendix of this document, select maximum 5. Type 3 is of free choice; you can select up to 10.*

|  |  |
| --- | --- |
| Type 1 (max 5) | XX, XX, XX |
| Type 2 (max 5) | XX, XX, XX |
| Type 3 (Free choice, max 10) | XX, XX, XX |

*----------------------------------Page count starts here (maximum 14 pages) --------------------------------*

# I. EXCELLENCE

## I.1 Introduction: background and context

*Describe shortly the topic and state of the art of your proposal (introduction, challenge definition, topics being addressed, etc.)*

## I.2 Concept and objectives

*Enumerate the main goal and specific objectives of your research project and explain how they align with the topic being addressed by the proposal.*

## I.3 Research methodology including multidisciplinary approach

*Describe the overall design of the research to address the objectives (strategies, procedures, methodologies, experiments, potential risks), including ethical considerations such as participants’ consents, confidentiality issues, potential risks). How is the multidisciplinarity of CIBER utilized/incorporated in the proposal? To what extent can the multidisciplinarity of CIBER enhance/enrich the proposal?*

## I.4 Innovation and originality

*Highlight the innovative and originality aspects of the proposal.*

## I.5 Suitability of the selected company

*Explain and justify the selection of your seconding company and why it would be beneficial for your project research and career development. Highlight the intersectoral approach of the proposal.*

## I.6 Open Sciences practices

*Explain how the open science principles are considered in the proposal (e.g. data sharing, code sharing, open access publications, reproducibility and transparency).*

# II. impAct

## II.1 Identified CIBER hosting group and integration with the group

*Explain the expected impact of the planned research and training on your future career prospects (e.g. new competences, skills, professional maturity). Discuss the expected impacts of your research project on the research group (advancements in the field, international network, knowledge transfer, etc.)*

## II.2 Expected outcomes: impact of your research

*Explain how the project’s results are expected to make a difference in terms of impact at national and international level (social, scientific, industrial, etc.)*

## II.3 Measures for communication, exploitation and dissemination

*How will new knowledge generated be communicated, disseminated and exploited to maximize the impact of your project. In case a commercial application is envisaged, define de strategy for the management of intellectual property and foreseen protection measures such as patents.*

## II.4 Potential industry/clinical collaborations

*Benefits of the intersectoral approach of the proposal. How can collaboration with industry/clinical environments contribute to improve the research.*

# III. implementation

## III.1 Work Plan

*Describe shortly the work plan, broken down for 36 months, in work packages and tasks, including deliverables, milestones and risks. For the risks provide a short description of proposed measures/actions to mitigate the risks’ effects.*

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| WP | 1 | TITLE | | X | Months | MX - MX |
| Objective | | |  | | | |
| Description | | |  | | | |
| Tasks | | |  | | | |
| Deliverables | | | D1.1. XX (Month X); D1.2. XXX (Month X) | | | |
| Milestones | | | M1.1. XX (Month X); M1.2. XXX (Month X) | | | |
| Risks | | |  | | | |
|  | | | | | | |
| WP | 2 | TITLE | | X | Months | MX - MX |
| Objective | | |  | | | |
| Description | | |  | | | |
| Tasks | | |  | | | |
| Deliverables | | | D1.1. XX (Month X); D1.2. XXX (Month X) | | | |
| Milestones | | | M1.1. XX (Month X); M1.2. XXX (Month X) | | | |
| Risks | | |  | | | |
|  | | | | | | |

*Create as many as you need for WP2, WP3, etc.*

|  |  |
| --- | --- |
| Milestones List | |
| M1 |  |
|  |  |
|  |  |
|  |  |
|  |  |

|  |  |
| --- | --- |
| Risk List and contingency plan | |
| R1 |  |
|  |  |
|  |  |
|  |  |
|  |  |

*Describe the relevant resources, infrastructure, equipment and any other services that are available at CIBER and your future host group, and are* ***necessary for your research****.*

|  |  |
| --- | --- |
| Needed research infrastructures in your proposal | |
|  |  |
|  |  |

## III.2 Match of the host group

*Discuss the complementarities between your research experience and that of the research group. How the expertise and facilities of the hosting group are suitable to carry on successfully the proposed research. Explain the two-way transfer of knowledge between you and the hosting research group.*

*------------------------------------------Page count ends here-----------------------------------------------*

# ETHICAL ISSUES

*Please, note the ethics assessment does not count towards the total page count for the research proposal. For guidance see: Horizon Europe: how to complete your ethics self-assessment*

|  |  |  |
| --- | --- | --- |
| **ETHICAL ISSUES** | YES/NO | Page |
| HUMAN EMBRYOS/FOETUSES | | |
| Does your research involve Human Embryonic Stem Cells (hESCs)? |  |  |
| Does your research involve the use of human embryos? |  |  |
| Does your research involve the use of human foetal tissues / cells? |  |  |
| HUMANS | | |
| Does your research involve human participants? |  |  |
| Does your research involve physical interventions on the study participants? |  |  |
| HUMAN CELLS / TISSUES | | |
| Does your research involve human cells or tissues? |  |  |
| PROTECTION OF PERSONAL DATA | | |
| Does your research involve personal data collection and/or processing? |  |  |
| Does your research involve further processing of previously collected personal |  |  |
| ANIMALS | | |
| Does your research involve animals? |  |  |
| ENVIRONMENT PROTECTION | | |
| Does your research involve the use of elements that may cause harm to the environment, to animals or plants? |  |  |
| Does your research deal with endangered fauna and/or flora and/or protected areas? |  |  |
| Does your research involve the use of elements that may cause harm to humans, including research staff? |  |  |
| Does your research involve dual-use items in the sense of Regulation 428/2009, or other items for which an authorisation is required? |  |  |
| Could your research raise concerns regarding the exclusive focus on civil  applications? |  |  |
| Does your research have the potential for misuse of research results? |  |  |
| Are there any other ethics issues that should be taken into consideration? |  |  |
| ARTIFICIAL INTELLIGENCE | | |
| Does this activity involve the development, deployment and/or  use of Artificial Intelligence-based systems? |  |  |
| Could the AI based system/technique potentially stigmatize or discriminate against people (e.g. based on sex, race, ethnic or social origin, age, genetic features, disability, sexual orientation, language, religion or belief, membership to a political group, or membership to a national minority)? |  |  |
| Does the AI system/technique interact, replace or influence human decision-making processes (e.g. issues affecting human life, health, well-being or human rights, or economic, social or political decisions)? |  |  |
| Does the AI system/technique have the potential to lead to negative social (e.g. on democracy, media, labor market, freedoms, educational choices, mass surveillance) and/or environmental impacts either through intended applications or plausible alternative uses? |  |  |
| Does the AI to be developed/used in the project raise any other ethical issues not covered by the questions above (e.g., subliminal, covert or deceptive AI, AI that is used to stimulate addictive behaviors, lifelike humanoid robots, etc.)? |  |  |

# APPENDIX 1: MOBILITY TRACK

*This table serves to demonstrate the compliance with the MSCA mobility rule.*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Period** | **Country** | **Institution/Organization** | **Duration (years)** | **Position** |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

# APPENDIX 2: KeyWORDS

|  |  |  |
| --- | --- | --- |
| **Keywords – Type 1** | | |
| Biomarker | Regenerative medicine | E-health |
| Companion diagnostic | Electronics | 3D printing |
| Small molecules | Chemical technology | Nanomedicine |
| biological product | Software | Materials |
| Gene therapy | Imaging | Repurposing |
| Cell therapy | App |  |

|  |  |  |
| --- | --- | --- |
| **Keywords – Type 2** | | |
| Infectious and parasitic diseases | Diseases of the ear | Musculoskeletal system and connective tissue |
| Neoplasm-cancer-oncology | Cardiovascular | Genitourinary system |
| Hematological diseases and Immunological diseases | Aging | Congenital malformations and chromosomal abnormalities |
| Diseases of the nervous system | Respiratory system | Injury, poisoning and certain other consequences of external causes |
| Mental and behavioural disorders | Digestive system | External causes of morbidity and mortality |
| Endocrine,nutrional, and metabolic diseases | Skin and subcutaneous tissue | Rare diseases |
| Diseases of the eye | Diseases of the ear | Pediatric conditions |